Ketamine Treatment Options

A collection of 519 research studies where Ketamine is the interventional treatment. These studies are located in the United States. Ketamine is used for conditions such as Pain, Major Depressive Disorder and Depression.

Home

All Treatments

Ketamine

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

The OBSERVE Protocol

NCT06725277

Recruiting

This observational protocol is intended to provide long-term follow-up data on patients initiating or continuing treatment with either Spravato® or IV ketamine. This can provide us information on the patient acceptability and satisfaction, patterns of use, long-term effectiveness, and safety of the two approaches. This 5-year, 6-site study will enroll 450 total patients. The sites will comprise 3 academic medical centers and 3 community psychiatric practices.

Gender:

ALL

Ages:

All

Trial Updated:

05/02/2025

Locations: Mood Institute, Milford, Connecticut +5 locations

Conditions: Major Depression Disorder

Learn More ›

Ketamine-assisted Therapy for Advanced GI Cancer

NCT06077487

Terminated

This clinical trial evaluates whether it is possible to use a single dose of ketamine in combination with talk therapy to treat moderate to severe demoralization in patients with stage 3 or 4 gastrointestinal (GI) cancers who take opioids for cancer-related pain. Advanced stage gastrointestinal (GI) cancer patients often suffer from high rates of psychosocial distress and pain. Symptoms of anxiety are highly prevalent among gastrointestinal (GI) cancers patients. While opioid analgesia (pain rel... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/29/2025

Locations: University of California, San Francisco, San Francisco, California

Conditions: Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization

Learn More ›

Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19

NCT06821087

Enrolling By Invitation

Plain Language Summary: This study is a clinical trial to see if ketamine can help treat symptoms of Long COVID, especially fatigue and problems with thinking clearly (often called "brain fog"). Long COVID is a condition that affects people even after they have recovered from COVID-19, causing ongoing health issues like tiredness, memory problems, and difficulty concentrating. Right now, there are very few treatments available for these symptoms, and many people are looking for new options to feel better. What is the study trying to find out? Does ketamine help reduce fatigue and improve thinking skills in people with Long COVID? Does ketamine improve overall quality of life and mental health for people with Long COVID? Is ketamine safe and well-tolerated for people with Long COVID? How does ketamine affect the body's biological processes, like inflammation and brain function? How will the study work? The study will include 20 adults between 18 and 65 years old who have Long COVID symptoms like fatigue or brain fog. Participants will first meet with researchers to answer health questions, take surveys about their symptoms, and do tests to check their thinking skills. Some participants will also have a brain scan (MRI) and give a blood sample to look at markers of inflammation. Participants will then receive four ketamine treatments over two weeks at a specialized clinic. The ketamine will be given as an injection, with the dose slightly increasing during the treatment period. After six weeks, participants will return for follow-up tests to see if their symptoms have improved. This includes repeating the surveys, thinking tests, and for some, another MRI and blood test. Why ketamine? Ketamine is a medicine originally used for anesthesia but has also been found to help with depression and other mental health issues. Researchers think it might help with Long COVID symptoms because it can reduce inflammation in the brain and improve how the brain functions. People with Long COVID often have signs of inflammation and changes in brain chemicals, which ketamine might help balance. What are the potential benefits? Participants might experience less fatigue and clearer thinking after ketamine treatment. They could also feel better overall in terms of mood and quality of life. Since ketamine can work quickly, some people may notice improvements shortly after starting the treatment. What are the risks? Ketamine can cause side effects like feeling dizzy, anxious, or having an unusual sense of reality (sometimes called dissociation). It may also cause temporary increases in blood pressure or heart rate. All treatments will be carefully monitored by healthcare professionals to ensure safety. Who can participate? Adults aged 18-65 with Long COVID who have significant fatigue or thinking problems can join. People will not be able to participate if they have certain health conditions like severe heart disease, uncontrolled high blood pressure, or a history of severe mental health disorders. Why is this study important? Long COVID affects millions of people, and many are struggling to find treatments that work. This study is one of the first to explore ketamine as a potential treatment for Long COVID symptoms. If ketamine helps, it could lead to more research and eventually new treatment options for people living with Long COVID. Read Less

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

04/29/2025

Locations: UT Health Austin, Austin, Texas

Conditions: Long COVID

Learn More ›

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

NCT02782104

Completed

The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: Not set, Birmingham, Alabama +176 locations

Not set, Birmingham, Alabama

Not set, Little Rock, Arkansas

Not set, Garden Grove, California

Not set, Glendale, California

Not set, Oakland, California

Not set, Orange, California

Not set, San Diego, California

Not set, San Rafael, California

Not set, Hartford, Connecticut

Not set, New Haven, Connecticut

Not set, Gainesville, Florida

Not set, Miami, Florida

Not set, Orlando, Florida

Not set, Atlanta, Georgia

Not set, Chicago, Illinois

Not set, Hoffman Estates, Illinois

Not set, Joliet, Illinois

Not set, Maywood, Illinois

Not set, Skokie, Illinois

Not set, Iowa City, Iowa

Not set, Wichita, Kansas

Not set, Lake Charles, Louisiana

Not set, Shreveport, Louisiana

Not set, Baltimore, Maryland

Not set, Gaithersburg, Maryland

Not set, Boston, Massachusetts

Not set, New Bedford, Massachusetts

Not set, Watertown, Massachusetts

Not set, Worcester, Massachusetts

Not set, Rochester Hills, Michigan

Not set, O'Fallon, Missouri

Not set, Saint Charles, Missouri

Not set, Omaha, Nebraska

Not set, Cedarhurst, New York

Not set, New York, New York

Not set, Staten Island, New York

Not set, Hickory, North Carolina

Not set, Cincinnati, Ohio

Not set, Oklahoma City, Oklahoma

Not set, Allentown, Pennsylvania

Not set, Media, Pennsylvania

Not set, Philadelphia, Pennsylvania

Not set, Lincoln, Rhode Island

Not set, Providence, Rhode Island

Not set, Charleston, South Carolina

Not set, Austin, Texas

Not set, Dallas, Texas

Not set, Houston, Texas

Not set, Wichita Falls, Texas

Not set, Charlottesville, Virginia

Not set, Waukesha, Wisconsin

Not set, Banfield, Not set

Not set, Ciudad Autonoma de Buenos Aires, Not set

Not set, Ciudad Autónoma De Buenos Aires, Not set

Not set, Cordoba, Not set

Not set, La Plata, Not set

Not set, Mendoza, Not set

Not set, Rosario, Not set

Not set, Caulfield, Not set

Not set, Elizabeth Vale, Not set

Not set, Frankston, Not set

Not set, Vienna, Not set

Not set, Aalst, Not set

Not set, Brugge, Not set

Not set, Brussel, Not set

Not set, Heusden-Zolder, Not set

Not set, Liège, Not set

Not set, Yvoir, Not set

Not set, Belo Horizonte, Not set

Not set, Curitiba, Not set

Not set, Fortaleza, Not set

Not set, Passo Fundo, Not set

Not set, Porto Alegre, Not set

Not set, Recife, Not set

Not set, Rio de Janeiro, Not set

Not set, Sao Bernardo do Campo, Not set

Not set, Sao Paulo, Not set

Not set, Bourgas, Not set

Not set, Kardzhali, Not set

Not set, Pazardzhik, Not set

Not set, Pleven, Not set

Not set, Plovdiv, Not set

Not set, Rousse, Not set

Not set, Sofia, Not set

Not set, Varna, Not set

Not set, Vancouver, British Columbia

Not set, Kingston, Ontario

Not set, Ottawa, Ontario

Not set, Toronto, Ontario

Not set, Brno, Not set

Not set, Plzen, Not set

Not set, Prague, Not set

Not set, Praha 10, Not set

Not set, Praha 2, Not set

Not set, Praha 6, Not set

Not set, Tallinn, Not set

Not set, Tartu, Not set

Not set, Kuopio, Not set

Not set, Clermont-Ferrand Cedex 1, Not set

Not set, Douai, Not set

Not set, Nantes, Not set

Not set, Nîmes, Not set

Not set, Paris, Not set

Not set, Poitiers Cedex, Not set

Not set, Toulon Cedex, Not set

Not set, Berlin, Not set

Not set, Bochum, Not set

Not set, Mainz, Not set

Not set, Mittweida, Not set

Not set, Oranienburg, Not set

Not set, Pfaffenhofen, Not set

Not set, Budapest, Not set

Not set, Debrecen, Not set

Not set, Gyor, Not set

Not set, Pecs, Not set

Not set, Sopron, Not set

Not set, Szekszárd, Not set

Not set, Vác, Not set

Not set, Gwangju, Not set

Not set, Seoul, Not set

Not set, Kaunas, Not set

Not set, Kuala Lumpur, Not set

Not set, Guadalajara, Not set

Not set, Leon, Not set

Not set, Mexico City, Not set

Not set, Mexico, Not set

Not set, Monterrey, Not set

Not set, San Luis Potosi, Not set

Not set, Belchatow, Not set

Not set, Bialystok, Not set

Not set, Bydgoszcz, Not set

Not set, Gdansk, Not set

Not set, Leszno, Not set

Not set, Lublin, Not set

Not set, Warszawa, Not set

Not set, Bratislava, Not set

Not set, Liptovsky Mikulas, Not set

Not set, Rimavska Sobota, Not set

Not set, Roznava, Not set

Not set, Svidnik, Not set

Not set, Cape Town, Not set

Not set, Pretoria, Not set

Not set, Welgemoed, Not set

Not set, Alcorcón, Not set

Not set, Barcelona, Not set

Not set, Bilbao, Not set

Not set, Madrid, Not set

Not set, Oviedo, Not set

Not set, Palma, Not set

Not set, Pamplona, Not set

Not set, Sabadell, Not set

Not set, Salamanca, Not set

Not set, Sant Boi de Llobregat, Not set

Not set, Torrevieja, Not set

Not set, Vitoria-Gasteiz, Not set

Not set, Zamora, Not set

Not set, Halmstad, Not set

Not set, Lund, Not set

Not set, Skövde, Not set

Not set, Stockholm, Not set

Not set, Kaohsiung, Not set

Not set, New Taipei, Not set

Not set, Taichung, Not set

Not set, Taipei, Not set

Not set, Taoyuan, Not set

Not set, Adana, Not set

Not set, Ankara, Not set

Not set, Bursa, Not set

Not set, Istanbul, Not set

Not set, Kucukcekmece/Istanbul, Not set

Not set, Oanakkale, Not set

Not set, Samsun, Not set

Not set, Chesterfield, Not set

Not set, Derby, Not set

Not set, London, Not set

Not set, Northampton, Not set

Not set, Oxford, Not set

Conditions: Depressive Disorder, Treatment-Resistant

Learn More ›

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001

Completed

The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo along with standard care treatment, in reducing the symptoms of major depressive disorder (MDD) (an affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities, the mood disturbance is prominent and relatively persistent), including the risk for suicide as assessed by the Investigator, in participants who will be assess... Read More

Gender:

ALL

Ages:

Between 18 years and 64 years

Trial Updated:

04/25/2025

Locations: Not set, Birmingham, Alabama +13 locations

Conditions: Major Depressive Disorder

Learn More ›

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287

Completed

The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: Not set, New Haven, Connecticut +109 locations

Not set, New Haven, Connecticut

Not set, Miami, Florida

Not set, Marietta, Georgia

Not set, Iowa City, Iowa

Not set, Wichita, Kansas

Not set, Baltimore, Maryland

Not set, Watertown, Massachusetts

Not set, Cedarhurst, New York

Not set, New York, New York

Not set, Staten Island, New York

Not set, Cincinnati, Ohio

Not set, Allentown, Pennsylvania

Not set, Charleston, South Carolina

Not set, Dallas, Texas

Not set, Wichita Falls, Texas

Not set, Richland, Washington

Not set, Banfield, Not set

Not set, Buenos Aires, Not set

Not set, Ciudad Autonoma de Buenos Aires, Not set

Not set, Cordoba, Not set

Not set, La Plata, Not set

Not set, Mendoza, Not set

Not set, Rosario, Not set

Not set, Adelaide, Not set

Not set, Caulfield, Not set

Not set, Frankston, Not set

Not set, Melbourne, Not set

Not set, Innsbruck, Not set

Not set, Vienna, Not set

Not set, Brugge, Not set

Not set, Hasselt, Not set

Not set, Belo Horizonte, Not set

Not set, Fortaleza, Not set

Not set, Recife, Not set

Not set, Rio de Janeiro, Not set

Not set, Santo André, Not set

Not set, Sao Jose do Rio Preto, Not set

Not set, São Paulo, Not set

Not set, Bourgas, Not set

Not set, Kardzhali, Not set

Not set, Kazanlak, Not set

Not set, Pazardzhik, Not set

Not set, Pleven, Not set

Not set, Plovdiv, Not set

Not set, Rousse, Not set

Not set, Sofia, Not set

Not set, Varna, Not set

Not set, Helsinki, Not set

Not set, Kuopio, Not set

Not set, Paris, Not set

Not set, Poitiers, Not set

Not set, Toulon, Not set

Not set, TOURS cedex 9, Not set

Not set, Berlin, Not set

Not set, Bochum, Not set

Not set, Oranienburg-Sachsenhausen, Not set

Not set, Gwangju, Not set

Not set, Gyeonggi-do, Not set

Not set, Seoul, Not set

Not set, Kaunas, Not set

Not set, Silute, Not set

Not set, Vilnius, Not set

Not set, Ipoh, Not set

Not set, Johor Bahru, Not set

Not set, Kuala Lumpur, Not set

Not set, Acapulco, Not set

Not set, Durango, Not set

Not set, Mexico City, Not set

Not set, Mexico, Not set

Not set, Monterrey, Not set

Not set, Gdansk, Not set

Not set, Cape Town, Not set

Not set, Garsfontein, Not set

Not set, Pretoria, Not set

Not set, Badajoz, Not set

Not set, Bilbao, Not set

Not set, Madrid, Not set

Not set, Ourense, Not set

Not set, Oviedo, Not set

Not set, Sant Boi de Llobregat, Not set

Not set, Torrevieja, Not set

Not set, Valencia, Not set

Not set, Zamora, Not set

Not set, Goteborg, Not set

Not set, Halmstad, Not set

Not set, Lund, Not set

Not set, Skovde, Not set

Not set, Solna, Not set

Not set, Stockholm, Not set

Not set, Umea, Not set

Not set, Kaohsiung, Not set

Not set, New Taipei City, Not set

Not set, Taichung, Not set

Not set, Tainan, Not set

Not set, Taipei, Not set

Not set, Taoyuan County, Not set

Not set, Ankara, Not set

Not set, Bursa, Not set

Not set, Gaziantep, Not set

Not set, Istanbul, Not set

Not set, Kocaeli, Not set

Not set, Manisa, Not set

Not set, Bristol, Not set

Not set, Chesterfield, Not set

Not set, Derby, Not set

Not set, London, Not set

Not set, Middlesbrough, Not set

Not set, Northampton, Not set

Not set, Oxford, Not set

Not set, Preston, Not set

Conditions: Treatment-resistant Depression

Learn More ›

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041

Completed

The purpose of this study is to evaluate the efficacy of switching adult participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intranasal esketamine (56 milligram \[mg\] or 84 mg) plus a newly initiated oral antidepressant compared with switching to a newly initiated oral antidepressant (active comparator) plus intranasal placebo, in improving depressive symptoms. Efficacy will be assessed by the change f... Read More

Gender:

ALL

Ages:

Between 18 years and 64 years

Trial Updated:

04/25/2025

Locations: Atlanta Center for Medical Research, Atlanta, Georgia +29 locations

Atlanta Center for Medical Research, Atlanta, Georgia

Biomedical Research Foundation of Northwest Louisiana, Shreveport, Louisiana

CBH Health, Gaithersburg, Maryland

Adams Clinical, Watertown, Massachusetts

The Medical Research Network, LLC, New York, New York

IPS Research Company, Oklahoma City, Oklahoma

Beijing Anding Hospital of Capital Medical University, Beijing, Not set

Beijing HuiLong Guan Hospital, Beijing, Not set

Peking University Sixth Hospital, Beijing, Not set

The Second People's Hospital of Hunan Province / Brian Hospital of Hunan Province, Changsha, Not set

The second Xiangya Hospital of Central South University, Changsha, Not set

West China Hospital Sichuan University, Chengdu, Not set

Chongqing Mental Health Center, Chongqing, Not set

the 3rd Affiliated Hospital,Sun Yansen University, Guangzhou, Not set

Guangdong Provincial People's Hospital, Guangzhou, Not set

Hangzhou Seventh People's Hospital, Hangzhou, Not set

First Hospital, Zhejiang University Medical College, Hangzhou, Not set

The Second Affiliated Hospital of Zhejiang University, Hangzhou, Not set

Huzhou third people's Hospital, Hu Zhou, Not set

First Affiliated Hospital of Kunming Medical Unversity, Kunming City, Not set

Nanjing Brain Hospital Affilicated to Nanjing Medical University, Nanjing, Not set

The First Hospital of Hebei Medical University, Shijiazhuang, Not set

Tianjin Anding Hospital, Tianjin, Not set

Urumqi fourth Hospital, Urumqi, Not set

The first affiliated hospital of Xinjiang medical university, Urumqi, Not set

Renmin Hospital of Wuhan University, Wuhan, Not set

The First Affiliated Hospital of Xian Jiaotong University, Xi'an, Not set

Xi'an Mental Health Center, Xi'an, Not set

Xiamen Xianyue Hospital, Xia Men, Not set

The First Affiliated Hospital of Zhengzhou University, Zheng Zhou, Not set

Conditions: Depressive Disorder, Treatment-Resistant

Learn More ›

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585

Completed

The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.

Gender:

ALL

Ages:

Between 18 years and 64 years

Trial Updated:

04/25/2025

Locations: Not set, Birmingham, Alabama +50 locations

Not set, Birmingham, Alabama

Not set, Orange, California

Not set, San Rafael, California

Not set, Maitland, Florida

Not set, Atlanta, Georgia

Not set, Chicago, Illinois

Not set, Gaithersburg, Maryland

Not set, Boston, Massachusetts

Not set, Philadelphia, Pennsylvania

Not set, Dallas, Texas

Not set, Klecany, Not set

Not set, Litomerice, Not set

Not set, Plzen, Not set

Not set, Prague, Not set

Not set, Praha 10, Not set

Not set, Praha 6, Not set

Not set, Prerov, Not set

Not set, Berlin, Not set

Not set, Cham, Not set

Not set, Dresden, Not set

Not set, Gelsenkirchen, Not set

Not set, Halle (Saale), Not set

Not set, Leipzig, Not set

Not set, Mainz, Not set

Not set, Mannheim, Not set

Not set, Mittweida, Not set

Not set, Pfaffenhofen, Not set

Not set, Prien, Not set

Not set, Tübingen, Not set

Not set, Bialystok, Not set

Not set, Bydgoszcz, Not set

Not set, Gdansk, Not set

Not set, Krakow, Not set

Not set, Myslowice, Not set

Not set, Pruszkow, Not set

Not set, Torun, Not set

Not set, Tuszyn, Not set

Not set, Warszawa, Not set

Not set, Alcorcón, Not set

Not set, Barcelona, Not set

Not set, Córdoba, Not set

Not set, Malaga, Not set

Not set, Mostoles, Not set

Not set, Murcia, Not set

Not set, Palma, Not set

Not set, Pamplona, Not set

Not set, Sabadell, Not set

Not set, Salamanca, Not set

Not set, Santa Coloma De Gramanet, Not set

Not set, Vitoria Gasteiz, Not set

Not set, Vitoria-Gasteiz, Not set

Conditions: Treatment-resistant Depression

Learn More ›

A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

NCT05268497

Withdrawn

The purpose of this study is to explore feasibility of combining clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app with esketamine therapy in participants with Treatment-resistant Depression.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

04/25/2025

Locations: Yale University, New Haven, Connecticut +4 locations

Conditions: Depression

Learn More ›

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine

NCT02846519

Completed

The purpose of this study is to evaluate the pharmacokinetics of intranasally administered esketamine in healthy Han Chinese, Korean, Japanese, and Caucasian participants and to evaluate the effects of rifampin on the pharmacokinetics of intranasally administered esketamine in healthy Caucasian participants.

Gender:

ALL

Ages:

Between 20 years and 55 years

Trial Updated:

04/25/2025

Locations: Not set, Cypress, California

Conditions: Healthy

Learn More ›

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958

Completed

The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants with treatment-resistant depression (TRD).

Gender:

ALL

Ages:

Between 20 years and 64 years

Trial Updated:

04/25/2025

Locations: Not set, Birmingham, Alabama +24 locations

Conditions: Treatment Resistant Depressive Disorder

Learn More ›

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064

Completed

The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.

Gender:

ALL

Ages:

Between 18 years and 64 years

Trial Updated:

04/25/2025

Locations: Not set, Birmingham, Alabama +91 locations

Not set, Birmingham, Alabama

Not set, Little Rock, Arkansas

Not set, Garden Grove, California

Not set, Orange, California

Not set, San Diego, California

Not set, San Marcos, California

Not set, San Rafael, California

Not set, Bradenton, Florida

Not set, Miami, Florida

Not set, Orlando, Florida

Not set, Chicago, Illinois

Not set, Hoffman Estates, Illinois

Not set, Maywood, Illinois

Not set, Schaumburg, Illinois

Not set, Wichita, Kansas

Not set, Gaithersburg, Maryland

Not set, Boston, Massachusetts

Not set, Quincy, Massachusetts

Not set, Watertown, Massachusetts

Not set, Worcester, Massachusetts

Not set, Minneapolis, Minnesota

Not set, O'Fallon, Missouri

Not set, Saint Charles, Missouri

Not set, Omaha, Nebraska

Not set, New York, New York

Not set, Durham, North Carolina

Not set, Dayton, Ohio

Not set, Oklahoma City, Oklahoma

Not set, Media, Pennsylvania

Not set, Philadelphia, Pennsylvania

Not set, Lincoln, Rhode Island

Not set, Austin, Texas

Not set, Dallas, Texas

Not set, Houston, Texas

Not set, Woodstock, Vermont

Not set, Bothell, Washington

Not set, Middleton, Wisconsin

Not set, Aalst, Not set

Not set, Brugge, Not set

Not set, Brussel, Not set

Not set, Bruxelles, Not set

Not set, Gent, Not set

Not set, Hasselt, Not set

Not set, Heusden-Zolder, Not set

Not set, Liège, Not set

Not set, Spa, Not set

Not set, Yvoir, Not set

Not set, Belo Horizonte, Not set

Not set, Curitiba, Not set

Not set, Fortaleza, Not set

Not set, Passo Fundo, Not set

Not set, Porto Alegre, Not set

Not set, Rio de Janeiro, Not set

Not set, Santo André, Not set

Not set, Calgary, Alberta

Not set, Vancouver, British Columbia

Not set, Kingston, Ontario

Not set, Ottawa, Ontario

Not set, Toronto, Ontario

Not set, Montreal, Quebec

Not set, Parnu, Not set

Not set, Tallinn, Not set

Not set, Tartu, Not set

Not set, BESANCON Cedex, Not set

Not set, Clermont Ferrand, Not set

Not set, Douai, Not set

Not set, Issy-les-Moulineaux, Not set

Not set, La Tronche, Not set

Not set, Lille, Not set

Not set, Limoges, Not set

Not set, Montpellier Cedex 5, Not set

Not set, Nantes, Not set

Not set, Neuilly sur Marne, Not set

Not set, Nimes Cedex 9, Not set

Not set, Paris, Not set

Not set, Poitiers, Not set

Not set, Toulon, Not set

Not set, TOURS cedex 9, Not set

Not set, Budapest, Not set

Not set, Vác, Not set

Not set, Guadalajara, Not set

Not set, Leon, Not set

Not set, Mazatlan, Not set

Not set, Mexico City, Not set

Not set, Monterrey, Not set

Not set, San Luis Potosi, Not set

Not set, San Luis Potosí, Not set

Not set, Bratislava, Not set

Not set, Liptovsky Mikulas, Not set

Not set, Rimavska Sobota, Not set

Not set, Roznava, Not set

Not set, Svidnik, Not set

Conditions: Treatment-resistant Depression

Learn More ›

Browse by State

Ketamine treatment options in Alabama

Ketamine treatment options in Alaska

Ketamine treatment options in Arizona

Ketamine treatment options in Arkansas

Ketamine treatment options in California

Ketamine treatment options in Colorado

Ketamine treatment options in Connecticut

Ketamine treatment options in Delaware

Ketamine treatment options in District of Columbia

Ketamine treatment options in Florida

Ketamine treatment options in Georgia

Ketamine treatment options in Hawaii

Ketamine treatment options in Idaho

Ketamine treatment options in Illinois

Ketamine treatment options in Indiana

Ketamine treatment options in Iowa

Ketamine treatment options in Kansas

Ketamine treatment options in Kentucky

Ketamine treatment options in Louisiana

Ketamine treatment options in Maine

Ketamine treatment options in Montana

Ketamine treatment options in Nebraska

Ketamine treatment options in Nevada

Ketamine treatment options in New Hampshire

Ketamine treatment options in New Jersey

Ketamine treatment options in New Mexico

Ketamine treatment options in New York

Ketamine treatment options in North Carolina

Ketamine treatment options in North Dakota

Ketamine treatment options in Ohio

Ketamine treatment options in Oklahoma

Ketamine treatment options in Oregon

Ketamine treatment options in Maryland

Ketamine treatment options in Massachusetts

Ketamine treatment options in Michigan

Ketamine treatment options in Minnesota

Ketamine treatment options in Mississippi

Ketamine treatment options in Missouri

Ketamine treatment options in Pennsylvania

Ketamine treatment options in Rhode Island

Ketamine treatment options in South Carolina

Ketamine treatment options in South Dakota

Ketamine treatment options in Tennessee

Ketamine treatment options in Texas

Ketamine treatment options in Utah

Ketamine treatment options in Vermont

Ketamine treatment options in Virginia

Ketamine treatment options in Washington

Ketamine treatment options in West Virginia

Ketamine treatment options in Wisconsin

Ketamine treatment options in Wyoming